Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study

Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study

<b>: </b>Background: The optimal anti-angiogenic strategy as second-line treatment in <i>RAS</i> wild-type metastatic colorectal cancer (mCRC) treated with anti-EGFR (Epidermal Growth Factor Receptor) based first-line treatment is still debated. Methods: This multicenter, rea...

Full description

Bibliographic Details
Main Authors: Alessandro Parisi, Alessio Cortellini, Katia Cannita, Olga Venditti, Floriana Camarda, Maria Alessandra Calegari, Lisa Salvatore, Giampaolo Tortora, Daniele Rossini, Marco Maria Germani, Alessandra Boccaccino, Emanuela Dell’Aquila, Claudia Fulgenzi, Daniele Santini, Michele De Tursi, Nicola Tinari, Pietro Di Marino, Pasquale Lombardi, Susana Roselló Keränen, Marisol Huerta Álvaro, Ina Valeria Zurlo, Domenico Cristiano Corsi, Alessandra Emiliani, Nicoletta Zanaletti, Teresa Troiani, Pasquale Vitale, Riccardo Giampieri, Filippo Merloni, Mario Alberto Occhipinti, Paolo Marchetti, Michela Roberto, Federica Mazzuca, Michele Ghidini, Alice Indini, Ingrid Garajova, Federica Zoratto, Simona Delle Monache, Giampiero Porzio, Corrado Ficorella
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:Cancers
Subjects:
RAS wild-type mCRC
anti-angiogenics
second-line treatment
Aflibercept
Bevacizumab
Panitumumab
Online Access:https://www.mdpi.com/2072-6694/12/5/1259

Similar Items

Similar Items